Search results
Results from the WOW.Com Content Network
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...
ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...
Apixaban is indicated for the following: [4] To lower the risk of stroke and embolism in people with nonvalvular atrial fibrillation. Deep vein thrombosis (DVT) prevention. DVTs may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. Treatment of both DVT and PE. To reduce the risk of recurring DVT and PE after initial ...
Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2] Other side effects may include stomach upset , dizziness , anemia or increased blood levels of liver enzymes .
ELIQUIS demonstrated lower all-cause mortality (placebo group was 1.7%, compared with 0.8% and 0.5% in the ELIQUIS 2.5 mg and 5 mg groups, respectively), though the difference was not ...
It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis. Rivaroxaban was the first FXa inhibitor on the market and then followed by apixaban, edoxaban and betrixaban.
Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]
For premium support please call: 800-290-4726 more ways to reach us